The European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA). Itvisma can now be used in the European Union by children two years and older, teens and adults living with 5q SMA with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. The cream is designed to address […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!